Semaglutide Formulation for Soft Mist Inhaler Delivery

RDD Europe 2025 Conference Poster on Soft Mist Inhaler Delivery: Aerosolization of Wegovy® and Prototype Formulations of Semaglutide with MRX004 SMI

Delivery of large molecules such as peptides, proteins, mRNA, monoclonal antibodies, and a whole range of other complex molecules to the lungs creates new challenges for formulation and device design. Solution formulations are well established for these molecules and so nebulisers are often the first technology considered; however soft mist devices offer more efficient delivery and a more convenient device for the patient.

The objective of this study was to examine the feasibility of delivering a GLP-1 agonist, Semaglutide, using the Merxin Ltd MRX004 soft mist inhaler (MRX004 SMI). Testing examined the droplet size, using both laser diffraction (DSD, Malvern Spraytec) and a Next Generation Impactor (NGI, Copley Scientific), as well as the effect of delivery on the molecule’s purity using capillary electrophoresis (CE–SDS, Sciex PA800 Plus). This work looked at both currently marketed subcutaneous injection formulations and prototype formulations to investigate the effect of higher drug loading.

Request your copy of the RDD Europe 2025 conference poster on Semaglutide Formulation for Soft Mist Inhaler Delivery now - we’ll send it to you after the event.